AYTU BIOPHARMA, INC. Net Income Prediction

Market overview

Derived from AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818) 10-Q filing analysis

FINANCIAL prediction market

Implied probability (Yes)

75%

Closes

2026-12-31

More FINANCIAL markets

• NAV per Share Growth — 75% Yes
• Filing of 2026 Annual Report — 85% Yes
• Navan, Inc. Revenue Growth Projection — 75% Yes
• SPRU Annual Revenue Growth — 65% Yes
• GS Mortgage Securities Trust 2028-GSA3 - Continued Filing Compliance — 85% Yes
• Twist Bioscience Corp Q3 2026 Revenue Analysis — 75% Yes
• Net Written Premium Growth in 2026 — 75% Yes
• Stereotaxis, Inc. Operating Cash Flow Stability — 60% Yes

Browse all FINANCIAL markets →